293 related articles for article (PubMed ID: 15814668)
1. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
[TBL] [Abstract][Full Text] [Related]
2. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
[TBL] [Abstract][Full Text] [Related]
3. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors.
Poggi A; Prevosto C; Massaro AM; Negrini S; Urbani S; Pierri I; Saccardi R; Gobbi M; Zocchi MR
J Immunol; 2005 Nov; 175(10):6352-60. PubMed ID: 16272287
[TBL] [Abstract][Full Text] [Related]
4. UL16 binding proteins.
Cao W; He W
Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
[TBL] [Abstract][Full Text] [Related]
5. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
6. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?
Vivier E; Tomasello E; Paul P
Curr Opin Immunol; 2002 Jun; 14(3):306-11. PubMed ID: 11973127
[TBL] [Abstract][Full Text] [Related]
8. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.
Wu J; Chalupny NJ; Manley TJ; Riddell SR; Cosman D; Spies T
J Immunol; 2003 Apr; 170(8):4196-200. PubMed ID: 12682252
[TBL] [Abstract][Full Text] [Related]
9. Activation of V gamma 9V delta 2 T cells by NKG2D.
Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
[TBL] [Abstract][Full Text] [Related]
10. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells.
Ehrlich LI; Ogasawara K; Hamerman JA; Takaki R; Zingoni A; Allison JP; Lanier LL
J Immunol; 2005 Feb; 174(4):1922-31. PubMed ID: 15699119
[TBL] [Abstract][Full Text] [Related]
11. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
12. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
13. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.
Cosman D; Müllberg J; Sutherland CL; Chin W; Armitage R; Fanslow W; Kubin M; Chalupny NJ
Immunity; 2001 Feb; 14(2):123-33. PubMed ID: 11239445
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
15. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
16. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
[TBL] [Abstract][Full Text] [Related]
17. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.
Sutherland CL; Rabinovich B; Chalupny NJ; Brawand P; Miller R; Cosman D
Blood; 2006 Aug; 108(4):1313-9. PubMed ID: 16621962
[TBL] [Abstract][Full Text] [Related]
18. NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica.
Dejaco C; Duftner C; Al-Massad J; Wagner AD; Park JK; Fessler J; Aigelsreiter A; Hafner F; Vega S; Sterlacci W; Grubeck-Loebenstein B; Tzankov A; Ness T; Boiardi L; Salvarani C; Schirmer M
Ann Rheum Dis; 2013 Nov; 72(11):1852-9. PubMed ID: 23417963
[TBL] [Abstract][Full Text] [Related]
19. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells.
Burgess SJ; Marusina AI; Pathmanathan I; Borrego F; Coligan JE
J Immunol; 2006 Feb; 176(3):1490-7. PubMed ID: 16424177
[TBL] [Abstract][Full Text] [Related]
20. Immunostimulation by induced expression of NKG2D and its MIC ligands in HTLV-1-associated neurologic disease.
Azimi N; Jacobson S; Tanaka Y; Corey L; Groh V; Spies T
Immunogenetics; 2006 May; 58(4):252-8. PubMed ID: 16568261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
